Rizatriptan
ریزاتریپتان
🧠 Nervous SystemTriptan
Market / country: 🇺🇸 USA
Maxalt-MLT (US)
🧮 Dose calculator
Acute migraine attack · Regimen source: FDA Rizatriptan ODT · 2.2FDA Rizatriptan ODT · 8.4
- • <40 kg: 5 mg; ≥40 kg: 10 mg. More than one dose in 24 h not established in children. Place on tongue; no liquid needed. FDA Rizatriptan ODT · 2.2FDA Rizatriptan ODT · 2.3
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Ischemic coronary disease, coronary vasospasm, stroke or TIA, peripheral vascular disease, uncontrolled hypertension; other triptans or ergots within 24 h. FDA Rizatriptan ODT · 4
- ⛔ Not established under 6 years. FDA Rizatriptan ODT · 8.4
Formulations
- 5 mg ODT — orally disintegrating tablet 🇺🇸 USA FDA Rizatriptan ODT · 3
- 10 mg ODT — orally disintegrating tablet 🇺🇸 USA FDA Rizatriptan ODT · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Rizatriptan ODT · 8.1
“Risk Summary Available human data on the use of rizatriptan benzoate in pregnant women are not sufficient to draw conclusions about drug-associated risk for major birth defects and miscarriage.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Rizatriptan ODT · 8.2
“Risk Summary There are no data on the presence of rizatriptan or any active metabolites in human milk, or on the effects of rizatriptan on the breastfed infant, or on milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Rizatriptan ODT · 8.4
“Safety and effectiveness in pediatric patients under 6 years of age have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Rizatriptan ODT · 8.5
“Although the pharmacokinetics of rizatriptan were similar in elderly (aged ≥65 years) and in younger adults (n=17), in general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA201914
- DailyMed (FDA label)FDA Rizatriptan ODT
- MedlinePlus (NIH)Rizatriptan
- WHO ATC/DDDN02CC04
- Darooyab (Iran)Rizatriptan
🇮🇷 Registered in Iran Darooyab · G-863/Rizatriptan
Dosage forms with Iranian generic codes, per Darooyab.
- 20203 · RIZATRIPTAN 10MG ORALLY DISINTEGRATING TAB · قرص ریزاتریپتان ۱۰ میلیگرم بازشونده
- 08596 · RIZATRIPTAN BENZOATE 0.5MG TAB · قرص ریزاتریپتان بنزوات ۰٫۵ میلیگرم
- 02455 · RIZATRIPTAN BENZOATE 10MG TAB · قرص ریزاتریپتان بنزوات ۱۰ میلیگرم
- 02286 · RIZATRIPTAN BENZOATE 5MG TAB · قرص ریزاتریپتان بنزوات ۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Rizatriptan ODT · 3FDA Rizatriptan ODT · 2.2FDA Rizatriptan ODT · 8.4FDA Rizatriptan ODT · 2.3FDA Rizatriptan ODT · 2.1FDA Rizatriptan ODT · 4FDA Rizatriptan ODT · 8.1FDA Rizatriptan ODT · 8.2FDA Rizatriptan ODT · 8.5FDA Rizatriptan ODT · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-863/Rizatriptan
- Clinical review⚠ Unverified